Posts Tagged ‘tirzepatide’

In the International Journal of Obesity, obesity medicine physician and researcher Caroline Apovian offers a compelling case to favor a prediabetes indication for GLP-1s. She writes: “The approval of a GLP-1 for prediabetes will change the landscape for prevention of T2DM and its complications due to early detection. Currently, most individuals at risk of T2DM […]

Back in March 2024, we welcomed the news of a door opening ever so slightly for Medicare Part D plans to cover GLP-1s in people with obesity and heart disease. So 18 months later, it’s reasonable to ask, how’s that working out for everyone? A new research letter in JAMA gives us an answer, but […]

Bimagrumab continues to be a enigma. We see flickering signs of good news – and then, inexplicably, it goes dark. The pattern repeated itself this week when news emerged that Lilly pulled the plug on a phase two study with bimagrumab and tirzepatide in persons with obesity and diabetes before it even enrolled a single […]

This week has been a flood of news from the EASD meeting in Vienna. Yesterday, the big news was an impressive win for kids 10-17 with type 2 diabetes in a study of tirzepatide. Researchers presented the SURPASS-PEDS trial and simultaneously published it in Lancet. At the end of the 30-week trial, tirzepatide in two […]

It’s almost funny. Except it’s not. This is deadly serious for people whose entire lives are shaped by obesity – people who need better access to care. The influential Institute for Clinical and Economic Review (ICER) issued a new draft report on the cost effectiveness of semaglutide and tirzepatide. In a nutshell, the report says […]

The short supply, high prices, and despicable insurance restrictions for advanced obesity medicines have created many problems. For example, compounding of these medicines has been and continues to be controversial – for good reasons. Now, FDA is recognizing one of the most pernicious threats to emerge from this situation – sketchy sellers of “research” peptides. […]

It is eye-popping really. Novo Nordisk issued a press release from the European Society of Cardiology (ESC) Congress over the weekend, with extravagant claims for Wegovy versus tirzepatide. Specifically, the claim was that “Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide.” This is quite an amazing claim to make. […]

Researchers presented and published two major studies of heart disease outcomes at the ESC Congress of the European Society of Cardiology over the weekend with strikingly different findings. In the REBOOT study, scientists found that beta blockers have no effect on outcomes when given to patients after a heart attack. None. People might be better […]

By now, it should be obvious. List prices for GLP-1 medicines like semaglutide and tirzepatide are fiction. If you had any doubt, read up on the deal Novo Nordisk just struck with GoodRx to sell both the Ozempic and Wegovy brands of semaglutide for $499 per month. This deal with GoodRx is happening for two […]

It should have been easy to see this coming. U.S. President Donald Trump complained about Americans being “ripped off” by drug prices that are much higher in the U.S. than other countries. He specifically called out the low price of obesity drugs in the UK. So Eli Lilly and Company knew just what to do. […]